Key result
High and increasing adiponectin linked to ~67% lower risk of incident metabolic syndrome.
Why the study?
The predictive value of changes in adiponectin levels over time for incident metabolic syndrome in a population-based cohort was unclear.
Do changes in adiponectin levels over time predict incident metabolic syndrome in a general population?
Cohort (n=1,110)
Do changes in adiponectin levels over time predict incident metabolic syndrome in a general population?
Both high baseline adiponectin and increases in adiponectin over time are associated with a significantly lower risk of developing metabolic syndrome, particularly in men.
Dynamic adiponectin rises may refine metabolic syndrome risk assessment; leaves open causality and intervention effects.
We investigated whether changes in adiponectin levels over time predict incident metabolic syndrome (MetS) in a population-based prospective study. In total, 1110 subjects were categorized into four groups according to their sex-specific median baseline adiponectin levels and the change in adiponectin levels at follow-up: low baseline adiponectin and decreased adiponectin during follow-up (LB&DF), low baseline adiponectin and increased adiponectin during follow-up (LB&IF), high baseline adiponectin and decreased adiponectin during follow-up (HB&DF), and high baseline adiponectin and increased adiponectin during follow-up (HB&IF). During the median 2.4-year follow-up period, 180 (16.2%) subjects developed MetS. Compared to the LB&DF group, the fully adjusted hazard ratio (95% confidence interval) for incident MS was the lowest in the HB&IF group (0.33, (0.17-0.63)), followed by the HB&DF group (0.58, (0.40-0.84)) and LB&IF group (0.63, (0.41-0.93)). This phenomenon was more prominent in men than in women. Among the individual MetS components, increased adiponectin levels during follow-up were significantly associated with lower risks of incident low high density lipoprotein (HDL) cholesterol and incident high blood pressure. This finding suggests that a change in adiponectin level, as well as the baseline adiponectin level, might have a clinical role in the development of MetS among men.
No takes yet. Share an insight, caveat, or question.
Huh et al. (2019) conducted a cohort in Metabolic Syndrome (n=1,110). High baseline and increased follow-up adiponectin levels vs. Low baseline and decreased follow-up adiponectin levels was evaluated on Incident metabolic syndrome (HR 0.33, 95% CI 0.17-0.63, p=<0.0001). High baseline adiponectin combined with increased adiponectin levels during follow-up was associated with a 67% lower risk of incident metabolic syndrome compared to low baseline and decreased adiponectin (HR 0.33).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: